

Jay S Skyler

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7725183/jay-s-skyler-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

248
papers

14,089
citations

61
h-index

113
g-index

287
ext. papers

16,394
ext. citations

9.6
avg, IF

6.3
L-index

#	Paper	IF	Citations
248	Evolving Approaches to Type 1 Diabetes Management 2022 , 315-322		
247	COVID-19 and metabolic disease: mechanisms and clinical management. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 786-798	18.1	33
246	Novel therapies with precision mechanisms for type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 364-377	15.2	18
245	Weekly Insulin Becoming a Reality. <i>Diabetes Care</i> , 2021 , 44, 1459-1461	14.6	0
244	Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions. <i>Artificial Organs</i> , 2021 , 45, 968-986	2.6	6
243	Index60 as an additional diagnostic criterion for type 1 diabetes. <i>Diabetologia</i> , 2021 , 64, 836-844	10.3	4
242	Consequences of the COVID-19 pandemic for patients with metabolic diseases. <i>Nature Metabolism</i> , 2021 , 3, 289-292	14.6	17
241	New insights into halting type 1 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 475-476	18.1	0
240	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2021 , 44, 2589-2625	14.6	26
239	The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2021 , 64, 2609-2652	10.3	21
238	A Wake-Up Call. <i>Diabetes Technology and Therapeutics</i> , 2020 , 22, 66	8.1	0
237	Practical recommendations for the management of diabetes in patients with COVID-19. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 546-550	18.1	463
236	Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials. <i>Diabetes</i> , 2020 , 69, 1827-1832	0.9	12
235	Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 427-433	6.7	2
234	The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study. <i>Diabetes Care</i> , 2020 , 43, 2668-2674	14.6	4
233	Corona Pandemic: Assisted Isolation and Care to Protect Vulnerable Populations May Allow Us to Shorten the Universal Lock-Down and Gradually Re-open Society. <i>Frontiers in Public Health</i> , 2020 , 8, 562901	6	1
232	Imagining a better future for all people with type 1 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2019 , 15, 623-624	15.2	3

231	Bringing closure: towards achieving a better understanding of Israel. <i>Lancet, The</i> , 2019 , 394, 559	40	1
230	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1716-1723	14.6	5
229	An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2019 , 381, 603-613	59.2	269
228	Associations of HbA1c with the timing of C-peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes. <i>Pediatric Diabetes</i> , 2019 , 20, 408-413	3.6	2
227	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. <i>Diabetes</i> , 2019 , 68, 1267-1276	0.9	45
226	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019 , 42, 1147-1154	14.6	138
225	Sleeping oxygen saturation, rapid eye movement sleep, and the adaptation of postprandial metabolic function in insulin sensitive and resistant individuals without diabetes. <i>Physiology and Behavior</i> , 2018 , 191, 123-130	3.5	1
224	Hope vs hype: where are we in type 1 diabetes?. <i>Diabetologia</i> , 2018 , 61, 509-516	10.3	33
223	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a EditorsRExpert Forum. <i>Diabetes Care</i> , 2018 , 41, 14-31	14.6	263
222	In Response to Carter and Heinemann: Insulin Concentration in Vials Randomly Purchased in Pharmacies in the United States: Considerable Loss in the Cold Supply Chain. <i>Journal of Diabetes Science and Technology</i> , 2018 , 12, 890-891	4.1	9
221	The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. <i>Diabetologia</i> , 2018 , 61, 84-92	10.3	19
220	Brief Commentary: Confusing Treatment Guidelines for Patients With Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2018 , 169, 253	8	3
219	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ECell Function and Improves HbA in New-Onset Type 1 Diabetes. <i>Diabetes Care</i> , 2018 , 41, 1917-1925	14.6	56
218	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. <i>Diabetes Care</i> , 2018 , 41, 1887-1894	14.6	59
217	Prevention of Type 1 Diabetes. <i>Endocrinology</i> , 2018 , 1-13	0.1	1
216	The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1. <i>Pediatric Diabetes</i> , 2018 , 19, 403-409	3.6	14
215	Prevention of Type 1 Diabetes. <i>Endocrinology</i> , 2018 , 451-463	0.1	
214	Insulin Sensitivity and Blood Pressure 2018 , 197-223		

213	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. <i>Diabetes Care</i> , 2018 , 41, 2560-2569	14.6	149
212	The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies. <i>Diabetes Technology and Therapeutics</i> , 2017 , 19, 183-187	8.1	15
211	Neurovascular uncoupling after rapid glycemic control as a trigger of the diabetic-uremic striatopallidal syndrome. <i>Parkinsonism and Related Disorders</i> , 2017 , 39, 89-90	3.6	6
210	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. <i>Diabetes</i> , 2017 , 66, 241-255	14.6	292
209	Diabetes Research and Care Through the Ages. <i>Diabetes Care</i> , 2017 , 40, 1302-1313	14.6	7
208	Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. <i>Diabetes Care</i> , 2017 , 40, 1494-1499	14.6	16
207	Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 1891-1902	27.4	88
206	Harold E. Lebovitz, MD: Legendary Diabetologist. <i>Diabetes Care</i> , 2016 , 39, 2118-2121	14.6	
205	Discovery of Phosphorylated Peripherin as a Major Humoral Autoantigen in Type 1 Diabetes Mellitus. <i>Cell Chemical Biology</i> , 2016 , 23, 618-628	8.2	13
204	Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 463-74	6.7	11
203	T1DM in 2014: Progress towards a bionic pancreas. <i>Nature Reviews Endocrinology</i> , 2015 , 11, 75-6	15.2	6
202	Immune intervention for type 1 diabetes, 2013-2014. <i>Diabetes Technology and Therapeutics</i> , 2015 , 17 Suppl 1, S80-7	8.1	2
201	Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study. <i>Diabetes Care</i> , 2015 , 38, 1742-9	14.6	60
200	Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2015 , 38, 1189-96	14.6	32
199	The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. <i>Diabetes Care</i> , 2015 , 38, 940-2	14.6	8
198	Adaptation of βCell and Endothelial Function to Carbohydrate Loading: Influence of Insulin Resistance. <i>Diabetes</i> , 2015 , 64, 2550-9	0.9	8
197	Prevention of type 1 diabetes 2015 , 539-549		
196	Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. <i>Diabetes Care</i> , 2015 , 38, 1964-74	14.6	435

195	The development, validation, and utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS). <i>Current Diabetes Reports</i> , 2015 , 15, 49	5.6	9
194	A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. <i>Diabetes Care</i> , 2015 , 38, 271-6	14.6	36
193	Effect of docosahexaenoic acid supplementation on inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes. <i>Pediatric Diabetes</i> , 2015 , 16, 271-9	3.6	23
192	Immune therapy for treating type 1 diabetes: challenging existing paradigms. <i>Journal of Clinical Investigation</i> , 2015 , 125, 94-6	15.9	5
191	Prevention and reversal of type 1 diabetes--past challenges and future opportunities. <i>Diabetes Care</i> , 2015 , 38, 997-1007	14.6	56
190	Immune intervention for type 1 diabetes, 2012-2013. <i>Diabetes Technology and Therapeutics</i> , 2014 , 16 Suppl 1, S85-91	8.1	1
189	Characterizing subgroups of type 1 diabetes. <i>Diabetes</i> , 2014 , 63, 3578-80	0.9	8
188	The artificial pancreas: current status and future prospects in the management of diabetes. <i>Annals of the New York Academy of Sciences</i> , 2014 , 1311, 102-23	6.5	98
187	Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 1065-9	6.7	11
186	Struggles with clinical translation of immune intervention trials. <i>Diabetes Care</i> , 2014 , 37, 1173-5	14.6	4
185	Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 206-14	6.7	7
184	B-lymphocyte depletion with rituximab and T cell function: two-year results. <i>Diabetes Care</i> , 2014 , 37, 453-9	14.6	144
183	Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. <i>Diabetes Care</i> , 2014 , 37, 979-84	14.6	25
182	Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. <i>Diabetes Care</i> , 2014 , 37, 1069-75	14.6	126
181	The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. <i>Diabetes Care</i> , 2013 , 36, 2615-20	14.6	77
180	The year in immune intervention for type 1 diabetes. <i>Diabetes Technology and Therapeutics</i> , 2013 , 15 Suppl 1, S88-95	8.1	5
179	Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth. <i>Diabetes Technology and Therapeutics</i> , 2013 , 15 Suppl 2, S2-13-S2-20	8.1	3
178	ATG in type 1 diabetes: an unanswered question. <i>Lancet Diabetes and Endocrinology</i> , 2013 , 1, 265-6	18.1	

177	Primary and secondary prevention of Type 1 diabetes. <i>Diabetic Medicine</i> , 2013 , 30, 161-9	3.5	61
176	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. <i>Lancet, The</i> , 2013 , 381, 1905-15	4.0	234
175	Decision-making in diabetes mellitus type 1. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013 , 25, 40-50	2.7	13
174	The compelling case for anti-CD3 in type 1 diabetes. <i>Diabetes</i> , 2013 , 62, 3656-7	0.9	13
173	George S. Eisenbarth: insulin and type 1 diabetes. <i>Diabetes Care</i> , 2013 , 36, 1437-42	14.6	5
172	An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. <i>Diabetes Technology and Therapeutics</i> , 2013 , 15, 609-18	8.1	23
171	Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. <i>Diabetes</i> , 2013 , 62, 4179-83	0.9	48
170	Use of continuous glucose monitoring in children and adolescents (*). <i>Pediatric Diabetes</i> , 2012 , 13, 215-23	6	85
169	Type 1 Diabetes 2012 , 65-94		1
168	Innate and adaptive immune gene expression profiles as biomarkers in human type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2012 , 170, 131-8	6.2	11
167	Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis. <i>Diabetes Care</i> , 2012 , 35, 1975-80	14.6	30
166	Management of Type 1 Diabetes 2012 , 95-113		
165	Type 1 Diabetes Mellitus: Immune Intervention 2012 , 157-173		
164	New Medications for the Treatment of Diabetes 2012 , 243-270		
163	Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. <i>Diabetes Care</i> , 2012 , 35, 1213-8	14.6	71
162	Meta-analysis of safety for low event-rate binomial trials. <i>Research Synthesis Methods</i> , 2012 , 3, 30-50	7.2	28
161	Type 1 diabetes mellitus: immune intervention. <i>International Journal of Clinical Practice</i> , 2012 , 66, 56-61	2.9	1
160	New medications for the treatment of diabetes. <i>International Journal of Clinical Practice</i> , 2012 , 66, 85-93	2.9	1

159	Prevention of autoimmune diabetes and induction of β cell proliferation in NOD mice by hyperbaric oxygen therapy. <i>Diabetes</i> , 2012 , 61, 1769-78	0.9	31
158	The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes. <i>Diabetes Care</i> , 2012 , 35, 1552-5	14.6	30
157	Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. <i>Diabetes</i> , 2012 , 61, 2066-73	0.9	216
156	The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. <i>Diabetes</i> , 2012 , 61, 1331-7	0.9	41
155	Effect of rituximab on human in vivo antibody immune responses. <i>Journal of Allergy and Clinical Immunology</i> , 2011 , 128, 1295-1302.e5	11.5	76
154	Comparison of two insulin assays for first-phase insulin release in type 1 diabetes prediction and prevention studies. <i>Clinica Chimica Acta</i> , 2011 , 412, 2128-31	6.2	13
153	Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2011 , 378, 412-9	4.0	403
152	Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. <i>Lancet, The</i> , 2011 , 378, 319-27	4.0	263
151	A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. <i>Pediatric Diabetes</i> , 2011 , 12, 85-90	3.6	11
150	Immune intervention for type 1 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2011 , 65, 61-70	2.9	18
149	Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. <i>Clinical Immunology</i> , 2011 , 139, 290-301	9	22
148	Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. <i>Diabetes</i> , 2011 , 60, 1-8	0.9	89
147	A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. <i>Diabetes Care</i> , 2011 , 34, 2435-7	14.6	21
146	Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. <i>Diabetes Care</i> , 2011 , 34, 1785-7	14.6	33
145	Development of autoantibodies in the TrialNet Natural History Study. <i>Diabetes Care</i> , 2011 , 34, 1897-901	14.6	47
144	Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes. <i>PLoS ONE</i> , 2011 , 6, e26471	3.7	33
143	Immunomodulation for type 1 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2010 , 64, 59-63	0.9	4
142	Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management. <i>International Journal of Clinical Practice</i> , 2010 , 64, 305-15	2.9	50

141	Prognostic performance of metabolic indexes in predicting onset of type 1 diabetes. <i>Diabetes Care</i> , 2010 , 33, 2508-13	14.6	40
140	Continuous subcutaneous insulin infusion--an historical perspective. <i>Diabetes Technology and Therapeutics</i> , 2010 , 12 Suppl 1, S5-9	8.1	12
139	Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. <i>Diabetes Care</i> , 2010 , 33, 826-32	14.6	114
138	Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). <i>Diabetes</i> , 2010 , 59, 2386-9	0.9	28
137	Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. <i>Diabetes</i> , 2010 , 59, 679-85	0.9	100
136	Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants. <i>Diabetes Care</i> , 2010 , 33, 620-5	14.6	44
135	Continuous glucose monitoring: an overview of its development. <i>Diabetes Technology and Therapeutics</i> , 2009 , 11 Suppl 1, S5-10	8.1	39
134	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. <i>Diabetes Care</i> , 2009 , 32, 187-92	14.6	13
133	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. <i>Diabetes Care</i> , 2009 , 32, 187-92	14.6	500
132	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. <i>Circulation</i> , 2009 , 119, 351-7	16.7	265
131	Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2009 , 32, 2269-74	14.6	196
130	Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2009 , 32, 1603-7	14.6	45
129	Central obesity and insulin resistance in the cardiometabolic syndrome: pathways to preclinical cardiovascular structure and function. <i>Journal of the Cardiometabolic Syndrome</i> , 2009 , 4, 63-71		17
128	Challenges in developing endpoints for type 1 diabetes intervention studies. <i>Diabetes/Metabolism Research and Reviews</i> , 2009 , 25, 694-704	7.5	12
127	The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. <i>Pediatric Diabetes</i> , 2009 , 10, 97-104	3.6	131
126	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 298-304	15.1	272
125	Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. <i>New England Journal of Medicine</i> , 2009 , 361, 2143-52	59.2	717
124	High-dose insulin therapy: is it time for U-500 insulin?. <i>Endocrine Practice</i> , 2009 , 15, 71-9	3.2	96

123	Unexplained hyperglycemia in continuous subcutaneous insulin infusion: evaluation and treatment. <i>The Diabetes Educator</i> , 2008 , 34, 327-33	2.5	20
122	Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 1 diabetes: A 3-year randomized controlled trial. <i>Diabetes Research and Clinical Practice</i> , 2008 , 82, 238-46	7.4	18
121	Latent autoimmune diabetes in adults: the search for interventions continues. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008 , 4, 600-1		
120	A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. <i>Diabetes Care</i> , 2008 , 31, 528-33	14.6	88
119	Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2008 , 31, 2188-92	14.6	57
118	Prevention of type 1 diabetes: the time has come. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008 , 4, 334-43		39
117	DIABETES MELLITUS: OLD ASSUMPTIONS AND NEW REALITIES 2008 , 23-32		
116	Type 1 Diabetes TrialNet--an international collaborative clinical trials network. <i>Annals of the New York Academy of Sciences</i> , 2008 , 1150, 14-24	6.5	81
115	Update on worldwide efforts to prevent type 1 diabetes. <i>Annals of the New York Academy of Sciences</i> , 2008 , 1150, 190-6	6.5	51
114	Pulmonary insulin delivery--state of the art 2007. <i>Diabetes Technology and Therapeutics</i> , 2007 , 9 Suppl 1, S1-3	8.1	5
113	Prediction and prevention of type 1 diabetes: progress, problems, and prospects. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 768-71	6.1	42
112	Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2007 , 30, 38-42	14.6	52
111	Cellular therapy for type 1 diabetes: has the time come?. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1599-600	27.4	15
110	Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. <i>Diabetes Care</i> , 2007 , 30, 579-85	14.6	63
109	Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. <i>Archives of Internal Medicine</i> , 2007 , 167, 148-54		150
108	Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2006 , 29, 643-9	14.6	127
107	PROactive: A Sad Tale of Inappropriate Analysis and Unjustified Interpretation. <i>Clinical Diabetes</i> , 2006 , 24, 63-65	2.9	15
106	Pulmonary insulin update. <i>Diabetes Technology and Therapeutics</i> , 2005 , 7, 834-9	8.1	3

105	Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. <i>Diabetes Care</i> , 2005 , 28, 1630-5	14.6	236
104	Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. <i>Diabetes Care</i> , 2005 , 28, 1068-76	14.6	492
103	HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure. <i>Cardiovascular Toxicology</i> , 2004 , 4, 303-16	3.4	31
102	Diabetes mellitus: pathogenesis and treatment strategies. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 4113-7	3.3	155
101	Diabetes Mellitus: Pathogenesis and Natural History 2004 , 11-27		2
100	Diabetes trends in the USA. <i>Diabetes/Metabolism Research and Reviews</i> , 2002 , 18 Suppl 3, S21-6	7.5	96
99	Evidence for Glycated Hemoglobin Targets from the Diabetes Control and Complications Trial. <i>Endocrine Practice</i> , 2002 , 8, 27-30	3.2	3
98	Inhaled human insulin treatment in patients with type 2 diabetes mellitus. <i>Annals of Internal Medicine</i> , 2001 , 134, 203-7	8	153
97	Modeling preclinical cardiovascular risk for use in epidemiologic studies: Miami community health study. <i>American Journal of Epidemiology</i> , 2001 , 154, 765-76	3.8	5
96	Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. <i>Lancet, The</i> , 2001 , 357, 331-5	4.0	250
95	Microvascular complications. Retinopathy and nephropathy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2001 , 30, 833-56	5.5	39
94	Therapeutic controversy: prevention and treatment of diabetes in children. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 494-522	5.6	41
93	Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. <i>Diabetes Research and Clinical Practice</i> , 2000 , 47, 177-84	7.4	356
92	Continuous Glucose Monitoring Symposium. <i>Diabetes Technology and Therapeutics</i> , 2000 , 2, 5-5	8.1	8
91	FreeStyle: a small-volume electrochemical glucose sensor for home blood glucose testing. <i>Diabetes Technology and Therapeutics</i> , 2000 , 2, 221-9	8.1	53
90	The economic burden of diabetes and the benefits of improved glycemic control: the potential role of a continuous glucose monitoring system. <i>Diabetes Technology and Therapeutics</i> , 2000 , 2 Suppl 1, S7-12	8.1	21
89	Now Is the Time to Prevent Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 495-498	5.6	3
88	Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study. <i>Diabetes Care</i> , 1999 , 22, 1092-6	14.6	60

87	Aberrant parasympathetic and hemodynamic function distinguishes a subgroup of psychologically distressed individuals with asymptomatic type-I diabetes mellitus. <i>International Journal of Behavioral Medicine</i> , 1999 , 6, 78-94	2.6	6
86	History of gestational diabetes, insulin resistance and coronary risk. <i>Journal of Diabetes and Its Complications</i> , 1999 , 13, 216-23	3.2	45
85	New diabetes criteria and clinical implications. <i>Drugs</i> , 1999 , 58 Suppl 1, 1-2; discussion 75-82	12.1	1
84	Cigarette smoking, alcohol use, and physical activity in relation to serum leptin levels in a multiethnic population: The Miami Community Health Study. <i>Annals of Epidemiology</i> , 1999 , 9, 108-13	6.4	75
83	The relation of fasting insulin to blood pressure in a multiethnic population: the Miami Community Health Study. <i>Annals of Epidemiology</i> , 1998 , 8, 236-44	6.4	6
82	Cholesterol control: long-term benefit of pancreas-kidney transplantation with FK 506 immunosuppression. <i>Transplantation Proceedings</i> , 1998 , 30, 513-4	1.1	16
81	Prevention of type 1 diabetes. <i>Medical Clinics of North America</i> , 1998 , 82, 739-55	7	33
80	Targeted glycemic control in type 2 diabetes. <i>The Journal of the Florida Medical Association</i> , 1998 , 85, 7-15		1
79	Insulin therapy in type II diabetes: who needs it, how much of it, and for how long?. <i>Postgraduate Medicine</i> , 1997 , 101, 85-90, 92-4, 96	3.7	18
78	Glucose control in type 2 diabetes mellitus. <i>Annals of Internal Medicine</i> , 1997 , 127, 837-9	8	6
77	Tactics for type I diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 1997 , 26, 647-57	5.5	5
76	Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: evidence for augmentation of chimerism. <i>Transplantation Proceedings</i> , 1997 , 29, 1207-8	1.1	19
75	Combined octreotide and insulin therapy in acromegaly. <i>Endocrine Practice</i> , 1997 , 3, 19-21	3.2	
74	Diabetic complications. The importance of glucose control. <i>Endocrinology and Metabolism Clinics of North America</i> , 1996 , 25, 243-54	5.5	108
73	Insulin sensitivity and blood pressure in a biethnic sample: the Miami Community Health Study. <i>Journal of Clinical Epidemiology</i> , 1996 , 49, 859-64	5.7	8
72	Adolescents With Diabetes: Gender Differences in Psychosocial Functioning and Glycemic Control. <i>Childrens Health Care</i> , 1995 , 24, 61-78	0.9	96
71	Hypertension in patients with diabetes mellitus. <i>American Journal of Hypertension</i> , 1995 , 8, 100s-105s	2.3	16
70	Use of FK 506 in simultaneous pancreas/kidney transplantation: lack of impairment of glycemic or lipid metabolism. <i>Transplantation Proceedings</i> , 1995 , 27, 3119-20	1.1	10

69	The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. <i>Transplantation Proceedings</i> , 1995 , 27, 3123-4	1.1	13
68	Splanchnic and systemic absorption of intraperitoneal insulin using a new double-tracer method. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1994 , 266, E750-9	6	12
67	Effect of cyclosporine A on serum tumor necrosis factor alpha in new-onset type I (insulin-dependent) diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 1994 , 8, 40-4	3.2	5
66	Resting parasympathetic status and cardiovascular response to orthostatic and behavioral challenges in type I insulin-dependent diabetes mellitus. <i>International Journal of Behavioral Medicine</i> , 1994 , 1, 137-62	2.6	2
65	Combined kidney/pancreas transplantation in diabetes mellitus. <i>The Journal of the Florida Medical Association</i> , 1994 , 81, 339-43		
64	SSCI presidential address: challenges of the future. <i>American Journal of the Medical Sciences</i> , 1993 , 306, 5-9	2.2	
63	The winds of change. <i>Diabetes</i> , 1993 , 42, 637-42	0.9	2
62	Human insulin after 10 years. <i>Diabetes Care</i> , 1993 , 16 Suppl 3, 1-3	14.6	18
61	Effects of an anti-CD5 immunoconjugate (CD5-Plus) in recent onset type I diabetes mellitus: A preliminary investigation. <i>Journal of Diabetes and Its Complications</i> , 1993 , 7, 224-232	3.2	25
60	Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project Team. <i>Journal of Diabetes and Its Complications</i> , 1993 , 7, 224-32	3.2	8
59	Morning versus bedtime isophane insulin in type 2 (non-insulin dependent) diabetes mellitus. <i>Diabetic Medicine</i> , 1992 , 9, 826-33	3.5	13
58	Cyclosporine in recent onset type I diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group. <i>Journal of Diabetes and Its Complications</i> , 1992 , 6, 77-88	3.2	30
57	The effect of ejaculation on albumin excretion rate. <i>Journal of Diabetes and Its Complications</i> , 1992 , 6, 163-5	3.2	2
56	Clinical review 17: Immunotherapy of type I diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 72, 3-9	5.6	23
55	Hyperinsulinemia and elevated blood pressure: cause, confounder, or coincidence?. <i>American Journal of Epidemiology</i> , 1990 , 132, 827-36	3.8	70
54	Developmental and Behavioral Aspects of Diabetes Management in Youngsters. <i>Childrens Health Care</i> , 1990 , 19, 132-139	0.9	124
53	Intensive insulin therapy for treatment of type I diabetes. <i>Diabetes Care</i> , 1990 , 13, 1265-83	14.6	89
52	Intensive insulin therapy: a personal and historical perspective. <i>The Diabetes Educator</i> , 1989 , 15, 33-9	2.5	12

51	Diabetes in adolescence: effects of multifamily group intervention and parent simulation of diabetes. <i>Journal of Pediatric Psychology</i> , 1989 , 14, 259-75	3.2	127
50	The association between heart rate and glycemia in adult diabetic subjects. <i>Diabetes Research and Clinical Practice</i> , 1988 , 5, 25-9	7.4	1
49	Necrobiosis lipoidica diabetorum: a clinicopathologic study. <i>Journal of the American Academy of Dermatology</i> , 1988 , 18, 530-7	4.5	63
48	The association between symptomatic sensory neuropathy and body stature in diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 1988 , 4, 95-8	7.4	14
47	Insulin pharmacology. <i>Medical Clinics of North America</i> , 1988 , 72, 1337-54	7	14
46	Influence of height on quantitative sensory, nerve-conduction, and clinical indices of diabetic peripheral neuropathy. <i>Diabetes Care</i> , 1987 , 10, 613-6	14.6	58
45	Development of the diabetes health belief scale. <i>The Diabetes Educator</i> , 1987 , 13, 292-7	2.5	30
44	Insulin-dependent diabetes mellitus. Flexibility in contemporary management. <i>Postgraduate Medicine</i> , 1987 , 81, 163-9, 172-4	3.7	9
43	Introduction: Symposium on immunology and diabetes. <i>Diabetes/metabolism Reviews</i> , 1987 , 3, 723-724		
42	Symposium on immunology and diabetes. <i>Diabetes/metabolism Reviews</i> , 1987 , 3, 857-1090		
41	Immune intervention studies in insulin-dependent diabetes mellitus. <i>Diabetes/metabolism Reviews</i> , 1987 , 3, 1017-35		20
40	Etiology and pathogenesis of insulin dependent diabetes mellitus. <i>Pediatric Annals</i> , 1987 , 16, 682-3, 686-93		4
39	Why control blood glucose? Influence on chronic complications of diabetes. <i>Pediatric Annals</i> , 1987 , 16, 713, 716-9, 723-4	1.3	8
38	Impaired vibratory perception and diabetic foot ulceration. <i>Diabetic Medicine</i> , 1986 , 3, 335-7	3.5	147
37	Use of plaster casts in the management of diabetic neuropathic foot ulcers. <i>Diabetes Care</i> , 1986 , 9, 149-52	14.6	66
36	Blood pressure, insulin, and glycemia in nondiabetic subjects. <i>American Journal of Medicine</i> , 1986 , 80, 861-4	2.4	132
35	Body stature as a risk factor for diabetic sensory neuropathy. <i>American Journal of Medicine</i> , 1986 , 80, 1031-4	2.4	67
34	The vibratory perception threshold in young diabetic patients: associations with glycemia and puberty. <i>Diabetes Care</i> , 1985 , 8, 605-7	14.6	54

33	Insulin action during pregnancy. Studies with the euglycemic clamp technique. <i>Diabetes</i> , 1985 , 34, 380-389		75
32	The flashlight test lacks validity as a screen for nocturnal hypoglycemia. <i>Diabetes Care</i> , 1984 , 7, 269-72	14.6	1
31	Medial plantar sensory response. Sensitive indicator of peripheral nerve dysfunction in patients with diabetes mellitus. <i>American Journal of Medicine</i> , 1984 , 76, 842-6	2.4	23
30	Stress and immune function in diabetes mellitus. <i>Clinical Immunology and Immunopathology</i> , 1983 , 27, 223-33		18
29	Dietary planning in insulin-dependent diabetes mellitus. <i>Pediatric Annals</i> , 1983 , 12, 652-7	1.3	2
28	Lack of effect of improved glycemc control on C-peptide secretion in patients without residual B-cell function. <i>Diabetes Care</i> , 1982 , 5, 334-6	14.6	7
27	Optimizing pumped insulin delivery. <i>Diabetes Care</i> , 1982 , 5, 135-9	14.6	50
26	Self-monitoring of blood glucose. <i>Medical Clinics of North America</i> , 1982 , 66, 1227-50	7	27
25	Glycemc control in insulin-dependent diabetes mellitus. Comparison of outpatient intensified conventional therapy with continuous subcutaneous insulin infusion. <i>American Journal of Medicine</i> , 1982 , 72, 673-80	2.4	103
24	Type I diabetes . . . regimens, targets, and caveats. <i>Diabetes Care</i> , 1982 , 5, 547-52	14.6	2
23	Diabetes mellitus: progress and directions. <i>American Journal of Medicine</i> , 1981 , 70, 101-4	2.4	12
22	Biosynthetic human insulin: progress and prospects. <i>Diabetes Care</i> , 1981 , 4, 140-3	14.6	14
21	An algebra for adiposity?. <i>Diabetes Care</i> , 1981 , 4, 328-9	14.6	
20	Algorithms for adjustment of insulin dosage by patients who monitor blood glucose. <i>Diabetes Care</i> , 1981 , 4, 311-8	14.6	181
19	Comparison of methods for blood glucose monitoring. <i>Diabetes Care</i> , 1981 , 4, 404-6	14.6	63
18	The relationship between maternal glycemia and macrosomia. <i>Diabetes Care</i> , 1980 , 3, 433-4	14.6	10
17	The importance of self-assessed health in patients with diabetes. <i>Diabetes Care</i> , 1980 , 3, 599-606	14.6	26
16	Blood glucose control during pregnancy. <i>Diabetes Care</i> , 1980 , 3, 69-76	14.6	42

15	A plethora of insulins. <i>Diabetes Care</i> , 1980 , 3, 638-9	14.6	2
14	The spectrum of insulin resistance. <i>Diabetes Care</i> , 1979 , 2, 319-22	14.6	4
13	Counterregulatory Hormones, Rebound Hyperglycemia, and Diabetic Control. <i>Diabetes Care</i> , 1979 , 2, 526-529	14.6	2
12	Instructing patients in making alterations in insulin dosage. <i>Diabetes Care</i> , 1979 , 2, 39-45	14.6	13
11	Diabetes and exercise: clinical implications. <i>Diabetes Care</i> , 1979 , 2, 307-11	14.6	16
10	complications of Diabetes Mellitus: Relationship to Metabolic Dysfunction. <i>Diabetes Care</i> , 1979 , 2, 499-502	14.6	116
9	Performance of technical skills of diabetes management: increased independence after a camp experience. <i>Diabetes Care</i> , 1978 , 1, 23-6	14.6	16
8	Diabetes mellitus and pregnancy. <i>Diabetes Care</i> , 1978 , 1, 49-63	14.6	27
7	Home Blood Glucose Monitoring As an Aid in Diabetes Management. <i>Diabetes Care</i> , 1978 , 1, 150-157	14.6	97
6	Diabetic retinopathy: a general survey. <i>Diabetes Care</i> , 1978 , 1, 127-37	14.6	17
5	Home blood glucose monitoring as an aid in diabetes management. <i>Diabetes Care</i> , 1978 , 1, 150-7	14.6	13
4	Effect of cyproheptadine administration on insulin secretion in acromegalic, diabetic and normal subjects. <i>Hormone and Metabolic Research</i> , 1975 , 7, 279-83	3.1	5
3	Growth retardation in the Lesch-Nyhan syndrome. <i>European Journal of Endocrinology</i> , 1974 , 75, 3-10	6.5	7
2	Prevention of Type 1 Diabetes29-48		
1	Prevention of Type 1 Diabetes43-68		